The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica by Mackie, SL et al.
This is a repository copy of The OMERACT Core Domain Set for Outcome Measures for 
Clinical Trials in Polymyalgia Rheumatica.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/116583/
Version: Accepted Version
Article:
Mackie, SL, Twohig, H, Neill, LM et al. (10 more authors) (2017) The OMERACT Core 
Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal 
of Rheumatology, 44 (10). 161109. pp. 1515-1521. ISSN 0315-162X 
https://doi.org/10.3899/jrheum.161109
© 2017 The Journal of Rheumatology. This is a pre-copy-editing, author-produced PDF of 
an article accepted for publication in The Journal of Rheumatology following peer review. 
The definitive publisher-authenticated version, Mackie, et al. (2017) The OMERACT Core 
Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal 
of Rheumatology, 44. 161109, is available online at: 
https://doi.org/10.3899/jrheum.161109.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in 
Polymyalgia Rheumatica 
 
Sarah L. Mackie1, Helen Twohig2, Lorna M Neill3, Eileen Harrison4, Beverley 
Shea5, Rachel J Black6, Tanaz A Kermani7, Peter A Merkel8, Christian Mallen9, 
Frank Buttgereit10, Chetan Mukhtyar11, Lee S Simon12, Catherine L Hill6,13 on 
behalf of the OMERACT PMR Working Group.  
 
Key indexing terms: 
Polymyalgia rheumatica, outcomes, OMERACT 
 
1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of 
Leeds, Leeds, UK 
2. Academic Unit of Primary Medical Care, University of Sheffield, Sheffield, 
UK 
3. PMR-GCA Scotland 
4. PMR and GCA North East 
5. Ottawa Hospital Research Institute and School of Epidemiology, Public 
Health and Preventative Medicine, University of Ottawa, Ottawa, Canada 
K1H 8L6 
6. Discipline of Medicine, The University of Adelaide, Adelaide, Australia 
7. Division of Rheumatology, University of California Los Angeles, Los 
Angeles, CA, USA 
8. Division of Rheumatology and Department of Biostatistics and 
Epidemiology, University of Pennsylvania, Philadelphia, PA, USA 
9. Primary Care and Health Sciences, Keele University, Keele, UK 
10. Department of Rheumatology and Clinical Immunology, Charite 
University Hospital Berlin, Germany 
11.  Norfolk and Norwich University Hospital, Norwich, UK 
12.  SDG LLC, Cambridge, Massachusetts, USA 
13.  Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia 
 
Grant support: NIHR Clinician Scientist Fellowship to Sarah Mackie; unrestricted 
grant from Horizon Pharmaceuticals. Rachel Black is the recipient of an 
Australian Rheumatology Association OMERACT Fellowship 2016. 
 
 
SL Mackie BM BCh PhD, Associate Clinical Professor and Honorary Consultant 
Rheumatologist, University of Leeds  s.l.mackie@leeds.ac.uk 
 
H Twohig MBChB, General Practitioner, Academic Unit of Primary Medical Care, 
University of Sheffield h.twohig@sheffield.ac.uk 
 
LM Neill, BSc, PMR-GCA Scotland and OMERACT Patient Research Partner, 
gdneill@gotadsl.co.uk 
 
E Harrison, BSc, PMR and GCA North East and OMERACT Patient Research 
Partner, harrisoneileen@gmail.com 
 B Shea, PhD, Senior Methodologist and Adjunct Professor, University of Ottawa 
bevshea@uottawa.ca 
 
R Black MBBS, Consultant Rheumatologist and Clinical Lecturer, Discipline of 
Medicine, The University of Adelaide Rachel.Black2@sa.gov.au 
 
TA Kermani MD MS, Assistant Clinical Professor, Division of Rheumatology, UCLA, 
TKermani@mednet.ucla.edu 
 
PA Merkel, MD MPH, Professor of Medicine and Epidemiology, Division of 
Rheumatology and Department of Biostatistics and Epidemiology, University of 
Pennsylvania pmerkel@upenn.edu 
 
CD Mallen PhD, NIHR Research Professor in General Practice, Arthritis Research UK 
Primary Care Centre, Research Institute for Primary Care, Keele University 
c.d.mallen@keele.ac.uk 
 
F Buttgereit MD, Professor of Rheumatology, Department of Rheumatology and 
Clinical Immunology, Charite University Hospital Berlin frank.buttgereit@charite.de 
 
C Mukhtyar MD, Consultant Rheumatologist, Norfolk and Norwich University 
Hospital, UK CHETAN.MUKHTYAR@nnuh.nhs.uk 
 
L S Simon MD, Principal, SDG LLC, Cambridge, Massachusetts lssconsult@aol.com 
 
C Hill MD, Clinical Professor and Consultant Rheumatologist, Discipline of Medicine, 
The University of Adelaide Catherine.Hill@sa.gov.au 
 
 
 
Corresponding author and reprint requests to Sarah Mackie, Leeds Institute of 
Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West 
Yorkshire LS7 4SA, United Kingdom 
 
Running footer: PMR core domain set 
2351 words 
  
Abstract 
 
Background. 
To inform development of a core domain set for outcome measures for clinical 
trials in polymyalgia rheumatica (PMR), we previously conducted patient 
consultations, a systematic review, a Delphi study and two qualitative studies. 
 
Methods. 
Domains identified by 70% or more of physicians and/or patients in the Delphi 
study were selected. The conceptual framework derived from the two qualitative 
research studies helped inform the meaning of each domain and its relationship 
to the others. The draft core domain set was refined by further discussion with 
patients and physicians who had participated in the Delphi study. At OMERACT 
2016 the domains were discussed and prioritized by eight Breakout Groups. 
Formal voting took place at the end of the Workshop and in the final Plenary. 
 
Results. 
93% of voters in the final plenary agreed that the inner core of domains 
considered mandatory for clinical trials of PMR should comprise: laboratory 
markers of systemic inflammation, pain, stiffness, and physical function. Patient ǲǳȋȌǤ
The research agenda included: psychological impact, weakness, physical activity, 
participation, sleep, imaging, and health-related quality of life. 
 
Conclusions. 
This core domain set was considered sufficiently well-defined that the next step 
will be to apply the OMERACT Filter 2.0 Instrument Selection Algorithm to select 
candidate instruments ǲǳǤ
allow instruments to be mapped onto each of our core domains in order to 
derive a core outcome set for PMR.  
Introduction 
 
Polymyalgia rheumatica (PMR) is an inflammatory disease of older people, 
causing pain and stiffness of the shoulders and hip girdles(1). The prevalence of 
PMR is about 1% in people over 50 years in the US (2) and UK (3). Many patients 
with PMR are managed by general practitioners / family physicians rather than 
rheumatologists(4, 5). The mainstay of treatment is long-term therapy with 
glucocorticoids. This treatment approach has the potential for toxicity, 
depending on glucocorticoid dose and patient-specific factors such as age(6, 7). 
The most recent PMR treatment guidelines conditionally recommend early 
addition of methotrexate to glucocorticoids, especially if there are risk factors for 
relapse, for prolonged therapy, or for glucocorticoid-related adverse effects(8). A 
stronger recommendation could not be made because the published randomized 
trials were small, with partly contradictory results. No high-quality evidence was 
identified evaluating any other potential glucocorticoid-sparing agent(8). A 
systematic review of domains and instruments in 35 PMR trials and longitudinal 
observational studies, conducted by the OMERACT PMR Working Group, found 
inconsistency and poor clarity of outcome measures recorded for PMR(9). The 
poor evidence base for management of PMR urgently requires improvement. Our 
objective is to produce guidance to researchers on a core outcome set for PMR: 
the minimal common set of outcome measurement instruments that should 
always be included in clinical trials of PMR, whether conducted in the 
community or specialist setting. Prior to recommending measurement 
instruments, it is necessary to define a core domain set of what it is that must be 
measured. 
 
Here we report on the process that was used to generate a core domain set for 
clinical trials of PMR based on a combination of stakeholder engagement, 
evidence synthesis, qualitative research, and a Delphi study. This is the first-ever 
core domain set developed for clinical trials of PMR and has had strong patient 
involvement throughout. This core domain set will inform selection and 
validation of instruments to be used in clinical trials of PMR. It will also be 
relevant to design of observational studies and studies to develop a PMR-specific 
patient-reported outcome measure. This report represents the culmination of a 
process reported in two prior OMERACT Special Interest Group reports(10, 11), 
work leading up to and during the 2016 OMERACT Workshop on PMR, and 
original primary research already published in full elsewhere (9, 12, 13). The 
new matter in this report includes a description of the methods and results of the 
Delphi survey and the process that was used to bring together multiple different 
sources of information (patient consultations, systematic literature review, one 
Delphi survey, two qualitative studies, further patient and clinician consultation 
to refine the draft core domain set, and a Workshop at OMERACT 2016) to arrive 
at a core domain set for PMR that was endorsed by 93% of voters in the final 
conference plenary, as well as highlighting areas that required further definition, 
such as Psychological Impact.  
 
 Scoping the problem 
We intend our core outcome set to apply to interventional research studies 
conducted in any setting, with a study duration of at least three months and 
typically one year(14). The domains selected would also be relevant to design of 
observational studies, which could be much larger or of longer duration.(15) We 
began by consulting stakeholders on all outcomes they considered important for 
patients diagnosed with PMR; in later phases we asked them to focus on clinical 
trials in order to give the context necessary for the prioritization of domains for a 
parsimonious core domain set.  
 
Patient involvement 
Clinical management decisions relating to patients diagnosed with PMR are ǯǢ-phase laboratory markers 
are used as supportive evidence(1). Defining what these symptoms are is 
therefore essential. Some of the patient research partners, including both co-
authors of the current report, involved over the life of this project were deeply 
involved in patient support groups (telephone and/or internet forums). Patient 
support groups were also helpful in identifying participants for our Delphi study.  
 
Patient consultations 
To inform the scope of the problem we started with a patient-driven 
consultation exercise(11). A convenience sample of 104 English-speaking 
patients with PMR under the care of rheumatologists from the UK and elsewhere 
in Europe were included and a modified nominal group technique was used, 
involving group discussions about three prespecified topics (symptoms, Ȍǡǯǲǳms for each topic. We reported these within the ICF framework of 
impairments, disability, and participation(11). 
 
Comparing outcome of patient consultations with systematic review 
findings 
Using the OMERACT Filter 2.0 Framework(16) we identified that outcomes 
reported in trials and observational studies of patient with PMR(9) did not 
always map well onto the messages emerging from our patient consultations ȋ ?ȌǤ	ǡǲǳǲǳ
also considered fatigue to be important. Patients preferred to describe their 
What is new since the last conference report: 
x Report of the methods and results of the Delphi survey of patients and 
clinicians 
x Report of the process that was used to bring together multiple 
different sources of information (patient consultations, systematic 
literature review, Delphi study, two qualitative studies, further patient 
and clinician consultation, and a Workshop at OMERACT 2016) 
x A core domain set for PMR endorsed by 93% of voters in the final 
conference plenary 
x A prioritized research agenda based on areas of continuing uncertainty 
or insufficient evidence, including psychological impact 
experience of PMR in terms of its impact on activities such as getting out of bed, 
turning over in bed, getting up from the sofa or toilet, driving, picking items up 
from the floor, opening doors, walking, and dressing. They found the symptoms 
themselves hard to describe. The psychological impact of their condition was 
also mentioned. We noted that research studies had no standard definitions of 
key PMR symptoms; for example, in the literature it was frequently unclear 
exactly how patients had been asked about their pain severity, where that pain 
was and what period of time was being asked about(9). Similarly the precise ǲǳ
published studies(9). There was also no standard method employed for 
reporting outcomes related to the burden of glucocorticoid therapy. Even the 
main daily dose and cumulative dose of glucocorticoid were not always well-
reported. 
 
Analysis of composite outcomes used in studies of PMR(17) showed that many 
included domains from both Pathophysiological Manifestations (acute phase 
markers and/or ability to elevate upper limbs) and Life Impact (symptom or 
patient-reported component). Although none of these composite outcomes has 
yet been completely validated according to the OMERACT Filter, they are 
informative regarding what aspects of PMR are considered important by experts 
in PMR.  
 
Delphi study 
In order to understand the differing perspectives of patients and physicians in 
prioritizing outcomes, we carried out a three-round Delphi study(10). We were 
advised by the National Research Ethics Service that ethical approval was not 
required. Although the disease (PMR) and its life impact may well be similar 
across countries, there are differences in the language used to describe this by 
patients. Whereas international English-speaking physicians are accustomed to 
using a common dialect (medical English) for accessing research studies and 
educational material, this is not necessarily the case for patients. To avoid 
potential misunderstanding arising from international differences in English 
vocabulary and usage, for our Delphi study we chose to recruit English-speaking 
patients from the UK. 
 
The Delphi study started with two groups: patients (from UK patient 
organisations, self-identifying as diagnosed with PMR) and clinicians. 55 patients 
with PMR took part. Of these, 46 completed round 2 and 34 completed round 3. 
85 clinicians with an interest in PMR were identified from Pubmed searches and 
attendance at relevant sessions at international meetings (ACR, EULAR). 60 
clinicians replied to round 1, 55 to round 2 and 53 to round 3.  Among the 60 
clinicians in round 1, 21 were from UK, 28 from elsewhere in Europe, 6 from 
North America, and 5 from Australasia. Self-reported expertise, other than 
clinical rheumatology and an interest in PMR, was: clinical trials research (26), 
outcomes research (19), epidemiology (11), qualitative research (5), general 
practice (5), and the allied health professions(2).  Potential domains were 	 ?Ǥ ?ȋǲǳǲǳǡ	 ?Ǥ ?Ȍ
and informed by the prior patient consultations and systematic review findings.  
 In order to avoid influence of the patients on the clinicians or vice versa, rounds 
1 and 2 were conducted separately. However, in order to identify areas of 
consensus and disagreement, we started with the same list of domains for 
everyone, using plain language rather than rheumatology jargon wherever Ǥ ?ǡǲǳ
option of adding any further domains to generate an expanded list. In round 2, 
each group was presented with the domains selected by >70% of respondents 
and were asked which other domains from the expanded list they considered 
essential for a core domain set for clinical trials of PMR. Those new domains 
selected by >70% of respondents in round 2 were adǯǤ
70% cut off, while arbitrary, is conventional for Delphi studies as well as being 
the usual level of consensus for OMERACT voting. Because of the variety of 
potential domains that seemed more relevant to glucocorticoid exposure, a 
separate item for glucocorticoid-related adverse effect was added in round 2. 
Results of rounds 1 and 2 are given in Table 2. In round 3, the domains finally 
selected by both groups were presented and opinions sought on the combined 
domain set. Free-text feedback at each stage allowed participants to give their 
reasoning for including or not including particular domains. A total of 91% of 
respondents (85% clinicians, 97% patients) agreed with the draft core domain 
set, with the major divergence of opinion appearing to be in relation to different ǲǳǤǲȏȐǳǡ
a technical diagnostic term in rheumatology, is a different domain from ǲǳǡȋ
than duration) was of key importance. 
 
Qualitative research on core PMR symptoms of pain and stiffness 
A qualitative study (13) explored in more depth what stiffness means to patients, 
and how it relates to pain. 50 patients with a clear, rheumatologist-confirmed 
diagnosis of PMR took part in eight focus groups; this convenience sample was 
recruited from three UK rheumatology clinics. Pain and stiffness usually ǤȋǲǡǳȌ
unpleasant experience, not necessarily related to movement. Stiffness (the 
experience of being prevented from movement) had profound consequences for 
daily functioning. Many patients suggested that measuring physical function 
would be the best way to measure stiffness itself. Fatigue was seen as separate 
from either pain or stiffness, but having impact on the broader experience of 
PMR. 
 
Qualitative research on the broader patient experience in PMR 
A second qualitative study explored the broader experience of PMR for patients 
treated in the community (12). The analysis of this study proceeded in parallel 
with the activities of the PMR Working Group and discussions before its 
publicǯǤ ? ? ? ?
and findings were presented. Based on the conceptual framework derived from 
the qualitative data we added the domain ǮPsychological Impactǯ, which had 
emerged as a surprisingly strong theme from the interviews.  
 
Domain prioritization  ǲǳǡȋǲǳȌǢǲǳǲǳ(18). The Inner Core should contain at least one domain 
chosen from each of the Core Areas including Pathophysiological Manifestations 
and Life Impact. It was recognized that the list of candidate domains derived 
from the Delphi was likely too long to be suitable for an Inner Core. Therefore, in 
the run-up to OMERACT 2016, informal email engagement was carried out with 
patients and physicians who had participated in the Delphi study. A long-list of 
domains that might be eligible for the Inner Core was proposed, based on all of 
the evidence presented above, and feedback was invited. This resulted in 
removal of the domain of Physician Global as several physicians told us that they 
felt Physician Global to be a composite construct, principally comprising 
information from laboratory markers of inflammation and the patient global 
(both of which were already on the long-list of domains). There were also 
questions about whether the underlying construct of Physician Global would 
genuinely be a scalar quantity or whether it was better conceptualized as a 
binary decision to escalate or reduce glucocorticoid dose, closer to the concept of ȀǤǲǳ
domain was Systemic Inflammation (Laboratory Blood Tests), the breakout 
discussions at the OMERACT Workshop focused on the Life Impact aspect of 
PMR. 
 
Breakout group discussions 
In order to encourage the discussion at breakout groups to draw on authentic 
patient experience, quotes from the qualitative interview were printed onto 
cards, and we handed a randomly-chosen card to each individual participant in 
the Breakout Group. Breakout Group Facilitators then asked their groups to 
prioritise the domains, based on the results of the research described and cited 
in the pre-conference reading, the work presented in the Plenary, and the quotes 
they had on their individual cards.  
 
Synthesis of advice from breakout groups  
Consistent with the conceptual model that emerged from both qualitative 
studies, pain/ache, stiffness and physical function were prioritized highly by the 
breakout groups as regards Life Impact (Table 3).  
 
Feedback from several breakout groups suggested that including Patient Global ǲǳǡ
since the qualitative data suggested such a strong overlap with physical function. 
Given the strong drive towards parsimony for this patient population, therefore, 
and given the lack of quantitative evidence to confirm or refute this suggestion, it ǲǳǲǳǤ 
 
Psychological Impact was felt to be important but to require further clarification 
of its meaning before inclusion in the Inner Core. The two candidate ǲǳ
the Delphi (Mood problems Ȃ ǲǳǡȌ ? ? ?
in the patient arm of the Delphi study. However, the qualitative study data 
suggested that Psychological Impact goes beyond the clinical constructs of 
simple anxiety or mood disturbance and in fact describes complex, evolving and ǯal state (for example, pre-diagnosis 
fears, relief at diagnosis followed by an ongoing sense of loss(12)Ǣǲǯǳ(13)) that are not necessarily well-described by the 
clinical constructs of anxiety or depression or indeed well-understood by 
clinicians. This was identified as a clear priority for further patient-centred 
research, perhaps with a view to developing a PMR- specific patient-reported 
outcome measure encompassing the psychological impact relating to this 
disease. 
 
Breakout groups also advised adding to the research agenda the following 
domains: Participation, Weakness, Glucocorticoid exposure, Physical activity, 
Sleep, Imaging, and Health-related Quality of Life. Some attendees also pointed 
out that some caution was required in the interpretation of the qualitative 
research because of the limited geographical area (UK) from which the 
participants were drawn.  
 
The Workshop concluded with a formal vote on whether each of our long-list ǲǳȋ ?ȌǤ
on these votes, which was also in line with the results of our qualitative studies, 
we entered the three Life Impact domains plus Systemic Inflammation 
(Laboratory Blood Tests) into the proposed Inner Core.  
 
Summary 
Based on all the quantitative and qualitative feedback received during the whole ǡǲǳȋ	 ?Ȍ	
session of the conference. 93% of voters agreed with the final proposed Inner 
Core Domain Set (laboratory markers of systemic inflammation, pain, stiffness, 
physical function). 
 
Future work 
Although there was substantial agreement on the inner core domains, the 
limitations of the voting procedure should be acknowledged; the system of one 
vote per attendeǯǯǤ
process also identified a substantial list of potential outcomes requiring further 
research in PMR. It will also be important to conduct further work with patients 
outside the UK, including non-English speakers, to assess generalizability of the 
concepts presented here. The OMERACT Handbook describes the next step, 
which will be to apply the OMERACT Filter 2.0 Instrument Selection Algorithm ȋǲǳȌǡo select candidate ǲǳ
whether each selected instrument should be included in the core outcome set. 
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 Figure Legends  
 
Figure 1. Proposed Core Domain Set for polymyalgia rheumatica clinical 
trials.   ǲǳ
Inner Core (mandatory to measure in all clinical trials of PMR), the middle circle 
denoting Important outcomes (strongly recommended to measure in PMR), and 
the outer circle denoting the Research Agenda (those domains that require ȌǤǲǳȋȌ
that should be reported by default in all clinical trials of any condition. The 
proposed contextual factors (bottom left) are suggestions we received regarding 
possible contextual factors and represent hypothesized factors only. HR-QoL: 
health-related quality of life. 
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